EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
Cancers of the head and neck and of the lung are associated with high morbidity and mortality rates that have remained relatively unchanged for more than 3 decades, despite advances in radiation therapies and chemotherapies over the same time. It is generally believed that the efficacy of standard t...
Saved in:
| Main Authors: | Martin Sattler, Oyewale Abidoye, Ravi Salgia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/tsw.2008.117 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01) -
Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01) -
The Effects of Silibinin Combined With EGFR‐TKIs in the Treatment of NSCLC
by: Xiaocen Wang
Published: (2025-02-01) -
Navigating the Evolving Treatment Paradigm for _EGFR_-Mutant NSCLC
by: Sebastian Kraus
Published: (2024-10-01) -
USP21-EGFR-Lyn axis drives NSCLC progression and therapeutic potential of USP21 inhibition
by: Ji Hye Shin, et al.
Published: (2025-07-01)